<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064220</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000310138</org_study_id>
    <secondary_id>DAIICHI-1027A-PRT007</secondary_id>
    <secondary_id>CPMC-IRB-20030512</secondary_id>
    <secondary_id>MSKCC-03061</secondary_id>
    <nct_id>NCT00064220</nct_id>
  </id_info>
  <brief_title>Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of soblidotin in treating patients who&#xD;
      have advanced or metastatic soft tissue sarcoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the objective tumor response rate in patients with advanced or metastatic soft&#xD;
           tissue sarcoma with prior exposure to anthracycline-based chemotherapy when treated with&#xD;
           soblidotin.&#xD;
&#xD;
        -  Determine the duration of response in patients treated with this drug.&#xD;
&#xD;
        -  Determine the time to tumor progression in patients treated with this drug.&#xD;
&#xD;
        -  Determine the median survival time and 12-month survival rate of patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the quantitative and qualitative toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive soblidotin IV over 1 hour on days 1 and 8. Treatment repeats every 3 weeks&#xD;
      for at least 2 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>soblidotin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed soft tissue sarcoma of 1 of the following tumor types:&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Malignant paraganglioma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Angiosarcoma, including hemangiopericytoma&#xD;
&#xD;
               -  Malignant peripheral nerve sheath tumor&#xD;
&#xD;
               -  Unclassified sarcoma&#xD;
&#xD;
               -  Miscellaneous sarcoma, including mixed mesodermal tumors of the uterus&#xD;
&#xD;
          -  The following tumor types are not eligible:&#xD;
&#xD;
               -  Gastrointestinal stromal tumor&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing's sarcoma&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
          -  Evidence of disease progression&#xD;
&#xD;
          -  Must have received 1 prior anthracycline-based chemotherapy regimen for metastatic&#xD;
             disease&#xD;
&#xD;
               -  Adjuvant chemotherapy is not considered 1 prior regimen unless tumor progressed&#xD;
                  within 12 months of therapy&#xD;
&#xD;
          -  At least 1 measurable lesion with indicator lesions outside of any prior radiation&#xD;
             field&#xD;
&#xD;
          -  No symptomatic brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  15 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and/or SGPT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if&#xD;
             liver metastases are present)&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction at least 40% by MUGA&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No baseline neurotoxicity grade 2 or greater&#xD;
&#xD;
          -  No concurrent serious infection&#xD;
&#xD;
          -  No psychiatric disorder that would preclude giving informed consent or complying with&#xD;
             study requirements&#xD;
&#xD;
          -  No other concurrent severe or uncontrolled medical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No other malignancy except nonmelanoma skin cancer, carcinoma in situ of the cervix,&#xD;
             or any other malignancy for which the patient has been in complete remission and off&#xD;
             all therapy for at least 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent anticancer biologic therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Localized radiotherapy to a non-indicator lesion for pain relief allowed provided&#xD;
                  all other methods of pain control are ineffective&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery and recovered&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior myelosuppressive therapy&#xD;
&#xD;
          -  At least 4 weeks since prior investigational drugs&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent anticancer cytotoxic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Pagan</last_name>
    <role>Study Chair</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - San Juan</name>
      <address>
        <city>San Juan</city>
        <zip>00927-5800</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer. 2006 Dec 15;107(12):2881-7.</citation>
    <PMID>17109446</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>May 15, 2012</last_update_submitted>
  <last_update_submitted_qc>May 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soblidotin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

